1.
Pittella C. [Impact of the Subcutaneous Formulation of Daratumumab in the Treatment of Multiple Myeloma: pharmacoeconomic aspects of the new formulation]. FE [Internet]. 2026 Nov. 18 [cited 2026 Nov. 19];27(1):81-90. Available from: https://journals.seedstm.com/index.php/FE/article/view/1615